Nevro Corp (NYSE:NVRO) – Equities researchers at William Blair lifted their FY2017 EPS estimates for shares of Nevro in a research note issued on Tuesday. William Blair analyst M. Kaczor now forecasts that the medical equipment provider will earn ($1.30) per share for the year, up from their prior forecast of ($1.47). William Blair also issued estimates for Nevro’s Q4 2017 earnings at ($0.20) EPS, Q1 2018 earnings at ($0.34) EPS, Q2 2018 earnings at ($0.23) EPS, Q3 2018 earnings at ($0.16) EPS, FY2018 earnings at ($0.92) EPS, Q1 2019 earnings at ($0.33) EPS, Q2 2019 earnings at ($0.13) EPS, Q4 2019 earnings at $0.04 EPS and FY2019 earnings at ($0.48) EPS.
Nevro (NYSE:NVRO) last released its quarterly earnings results on Monday, November 6th. The medical equipment provider reported ($0.21) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.02. Nevro had a negative net margin of 7.57% and a negative return on equity of 10.30%. The company had revenue of $82.26 million for the quarter, compared to analyst estimates of $80.50 million. During the same quarter last year, the firm posted ($0.14) earnings per share. The company’s quarterly revenue was up 35.0% compared to the same quarter last year.
Nevro (NVRO) opened at $77.40 on Thursday. Nevro has a 52-week low of $65.00 and a 52-week high of $99.63. The company has a market cap of $2,290.00, a P/E ratio of -53.38 and a beta of -0.83. The company has a debt-to-equity ratio of 0.59, a current ratio of 8.78 and a quick ratio of 6.81.
In other news, CFO Andrew H. Galligan sold 7,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were sold at an average price of $75.11, for a total value of $525,770.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Company insiders own 12.10% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of NVRO. Ameritas Investment Partners Inc. boosted its stake in Nevro by 17.3% during the second quarter. Ameritas Investment Partners Inc. now owns 2,432 shares of the medical equipment provider’s stock worth $181,000 after buying an additional 358 shares in the last quarter. PNC Financial Services Group Inc. acquired a new stake in Nevro during the second quarter worth $190,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in Nevro during the third quarter worth $211,000. Prudential Financial Inc. boosted its stake in Nevro by 13.8% during the second quarter. Prudential Financial Inc. now owns 2,878 shares of the medical equipment provider’s stock worth $214,000 after buying an additional 350 shares in the last quarter. Finally, Sterling Capital Management LLC acquired a new stake in Nevro during the second quarter worth $233,000.
WARNING: “Nevro Corp (NVRO) Forecasted to Post FY2017 Earnings of ($1.30) Per Share” was reported by Ticker Report and is the property of of Ticker Report. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3145036/nevro-corp-nvro-forecasted-to-post-fy2017-earnings-of-1-30-per-share.html.
Nevro Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.